TISSUE POLYPEPTIDE ANTIGEN IN TUMOR CYTOSOL - A NEW PROGNOSTIC INDICATOR IN PRIMARY BREAST-CANCER

被引：10
作者：
GION, M
MIONE, R
GATTI, C
DITTADI, R
LEON, A
CASTIGLIONI, C
NASCIMBEN, O
BRUSCAGNIN, G
机构：
[1] REG GEN HOSP, CTR ONCOL, I-30172 MESTRE, ITALY
[2] REG GEN HOSP, DIV SURG 2, I-30172 MESTRE, ITALY
[3] REG GEN HOSP, CTR ONCOL, DIV RADIOTHERAPY & NUCL MED, I-30122 VENICE, ITALY
来源：
BREAST CANCER RESEARCH AND TREATMENT | 1990年 / 17卷 / 01期
关键词：
BREAST CANCER; CYTOSOL; PROGNOSIS; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS;
D O I：
10.1007/BF01812680
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The assessment of the risk of relapse is a critical need in the management strategy of breast cancer patients. To date, the most reliable prognostic factor is axillary nodal status. Several other pathological and biological parameters are currently under evaluation. Since 1982 we have been studying the prognostic role of several tumor markers in breast cancer cytosol. Elevated cytosol concentrations of tissue polypeptide antigen (TPA) have been found to have a highly significant direct correlation with both prolonged relapse-free interval (RFI) and higher survival rate. The information provided by cytosol TPA was independent of both axillary nodal status and steroid receptor content. In patients with a low risk of relapse (no axillary metastases, estrogen and progesterone receptor positive), cytosol TPA was still a significant prognostic indicator.
引用
收藏
页码：15 / 21
页数：7
相关论文
共 39 条
[21]  
Gion M, 1986, Int J Biol Markers, V1, P33
[22]  
GION M, 1986, CANCER, V57, P917, DOI 10.1002/1097-0142(19860301)57:5<917::AID-CNCR2820570506>3.0.CO
[23]  
2-M
[24]  
HENDERSON IC, 1988, NEW ENGL J MED, V318, P443, DOI 10.1056/NEJM198802183180709
[25]  
HOWELL A, 1984, LANCET, V1, P588
[26]  
KJELLGREN K, 1979, CARCINOEMBRYONIC PRO, P607
[27]  
KUTE TE, 1981, CANCER RES, V41, P3524
[28]   A SUGGESTED FOLLOW-UP TIME FOR BREAST-CANCER PATIENTS [J].
LEIVONEN, MK ;
SAARIO, IA ;
PELTOKALLIO, P ;
TUOMINEN, L ;
KALIMA, TV .
BRITISH JOURNAL OF CANCER, 1986, 54 (05) :837-840
[29]  
MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163
[30]  
MEYER JS, 1977, CANCER, V40, P2290, DOI 10.1002/1097-0142(197711)40:5<2290::AID-CNCR2820400541>3.0.CO
1234